Aytu Bioscience Inc (NASDAQ:AYTU)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $1.67, but opened at $1.66. Aytu Bioscience shares last traded at $1.54, with a volume of 258,727 shares trading hands.
Several brokerages recently commented on AYTU. ValuEngine raised shares of Aytu Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Zacks Investment Research raised shares of Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Monday, April 20th. Finally, HC Wainwright assumed coverage on shares of Aytu Bioscience in a research note on Friday, May 29th. They issued a “buy” rating and a $3.00 price objective for the company.
The company’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.19. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.89 and a current ratio of 1.98.
A number of institutional investors have recently added to or reduced their stakes in AYTU. HighTower Advisors LLC purchased a new position in Aytu Bioscience during the first quarter worth about $25,000. HCR Wealth Advisors purchased a new position in Aytu Bioscience during the first quarter worth about $30,000. BlackRock Inc. boosted its holdings in Aytu Bioscience by 38.5% during the first quarter. BlackRock Inc. now owns 31,289 shares of the company’s stock worth $47,000 after purchasing an additional 8,699 shares during the last quarter. ETRADE Capital Management LLC purchased a new position in Aytu Bioscience during the first quarter worth about $111,000. Finally, Soleus Capital Management L.P. purchased a new position in Aytu Bioscience during the first quarter worth about $209,000. Institutional investors and hedge funds own 1.68% of the company’s stock.
Aytu Bioscience Company Profile (NASDAQ:AYTU)
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
See Also: Insider Trading – What You Need to Know
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.